A 75% insulin lispro/25% NPL mixture provides a longer duration of insulin activity compared with insulin lispro alone in patients with Type 1 diabetes

Diabetic Medicine

Volumn 20, Issue 11, 2003, Pages 946-952

  Roach, Paris ^a   Woodworth, J ^b   Gudat, U ^c   Cerimele, B ^d   Diebler, F ^e   Pein, M ^e,f   Dreyer, M ^e  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VERTEX PHARMACEUTICALS   (United States)

^c Aretaeus Sàrl   (Switzerland)

^d ELI LILLY AND COMPANY   (United States)

^e Bethanien Hospital   (Germany)

^f DFT Gesellschaft für Diabetesforschung und Therapie   (Germany)

Author keywords

Humalog; Insulin analogues; Insulin lispro; Insulin lispro high mix; Type 1 diabetes

Indexed keywords

HUMAN INSULIN; INSULIN LISPRO; ISOPHANE INSULIN; ANTIDIABETIC AGENT; DRUG DERIVATIVE; INSULIN;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVATION; DRUG MIXTURE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; TEST MEAL; ADULT; AREA UNDER THE CURVE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG COMBINATION; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT WITHDRAWAL;

ADULT; AREA UNDER CURVE; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INFUSIONS, INTRAVENOUS; INSULIN; MALE; TIME FACTORS; WITHHOLDING TREATMENT;

EID: 1542498654     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2003.01100.x     Document Type: Article

References (11)

1. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys (B28), Pro (B29)]-human insulin: a rapidly-absorbed analogue of human insulin. Diabetes 1994; 43: 396-402.
2. Torlone E, Pampanelli S, Lalli C, Del Sindaco P, Ramborti AM, Modarelli F et al. Effects of the short-acting insulin analog [Lys (B28), Pro (B29)] on postprandial blood glucose control in IDDM. Diabetes Care 1996; 19: 945-952.
3. Del Sindaco P, Ciofetta M, Lalli C, Perriello G, Pampanelli S, Torlone E et al. Use of the short-acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal. Diabetic Med 1998; 15: 592-600.
4. Lalli C, Ciofetta M, Del Sindaco P, Torlone E, Pampanelli S, Compagnucci P et al. Long-term intensive treatments of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care 1999; 22: 468-477.
5. 1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime. Diabetes Care 1999; 22: 795-800.
6. Heise T, Weyer C, Serwas A, Heinrichs S, Osinga J, Roach P et al. Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. Diabetes Care 1998; 21: 800-803.
7. Bowsher RR, Lynch RA, Brown-Augsburger P, Santa PF, Legan WE, Woodworth JR et al. Sensitive RIA for the specific determination of insulin lispro. Clin Chem 1999; 45: 104-110.
8. SAS Institute Inc. SAS/STAT User's Guide, Version 6, 4th edn. Cary, NC: SAS Institute Inc., 1989.
9. Heinemann L, Woodworth JR. Pharmacokinetics and glucodynamics of insulin lispro. Drugs Today 1998; 34: (Suppl. C) 23-36.
10. Heinemann L, Heise T, Wahl LC, Trautmann ME, Ampudia J, Starke AAR et al. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid actin insulin analogue [Lys9B28), Pro (B29)] human insulin. Diabetic Med 1996; 13: 625-629.
11. Colombel A, Murat A, Krempf M, Kuchly-Anton B, Charbonnel B. Improvement of blood glucose control in Type 1 diabetic patients treated with lispro and multiple NPH injections. Diabetic Med 1999; 16: 319-324.